# GLP-1 Drugs After Spinal Cord Injury: Three People Treated, Two Not

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-21 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/glp1-after-spinal-cord-injury

> In a controlled case series of five people with chronic spinal cord injury, three on weekly semaglutide lost weight, fat mass and visceral fat over 26 weeks while the two untreated participants gained on every measure.

## Key points

- Open-label controlled case series: 3 participants on weekly semaglutide for 26 weeks, 2 untreated controls.
- Treated averages: -6 kg body weight, -4.4 kg fat mass, -674 cm3 visceral fat, -17 mg/dL fasting glucose.
- Controls moved the opposite way on every measure, consistent with deterioration being the default trajectory after injury.
- Three people and two people. This justifies a trial; it is not a result.

Almost no obesity research enrolls people with chronic spinal cord injury, which leaves a group whose standard weight-loss advice depends on mobility they do not have. The one study we could find is a controlled case series: **three people** received weekly semaglutide for 26 weeks and **two** did not. The treated three lost weight, fat mass and visceral fat. The untreated two gained all three.[1] Five people make a very small study, but it is the best evidence that exists for this population.

## What was done

The study was an open-label, randomized drug intervention case series at a VA medical center and a rehabilitation institute. Five individuals with chronic spinal cord injury who met criteria for obesity and abnormal carbohydrate metabolism were assigned to weekly subcutaneous semaglutide or to no treatment for 26 weeks. Body composition was measured by DXA at baseline and at the end.[1]

*Average change over 26 weeks in three treated and two control participants.[1]*

|   | Semaglutide (n = 3) | No treatment (n = 2) |
| --- | --- | --- |
| Total body weight | −6 kg | +3.3 kg |
| Fat tissue mass | −4.4 kg | +4.5 kg |
| Total body fat % | −1.7% | +2.5% |
| Visceral adipose tissue | −674 cm³ | +991 cm³ |
| Fasting plasma glucose | −17 mg/dL | +11 mg/dL |
| HbA1c | −0.2% | +0.3% |

In every row the two groups move in opposite directions, which is why a study this small is worth reporting at all. The treated group improved, and the untreated group got worse over the same half-year on every measure taken.

> **Three people and two people.** An average across three participants can be driven by one of them. There is no blinding, the design is a case series rather than a trial, and no statistical comparison between groups is meaningful at this size. Read this as a signal that a proper trial is warranted, not as a result.

## Why the control arm is the interesting half

After spinal cord injury, body composition tends to shift toward fat, including visceral fat, through mechanisms that have little to do with willpower and a great deal to do with reduced muscle mass and altered energy expenditure. The control participants’ deterioration over 26 weeks is consistent with that being the default direction of travel.

That reframes what a treatment would need to achieve. In a population drifting toward more visceral fat and worse glycemia, an intervention that merely holds the line would be doing something. This one appeared to reverse it, in three people.

## What it does not answer

- Whether the effect holds in a larger group, or over longer than 26 weeks.
- How muscle is affected. DXA measured fat tissue mass, and lean tissue is already reduced in this population, but this study did not put muscle at its center.
- How the gastrointestinal side effects of these drugs interact with the bowel management routines many people with SCI depend on. That is a practical question and this study does not address it.
- Nothing here is a reason to change anything without the clinician who manages your injury. Autonomic and bowel considerations after SCI are specific, and general drug advice does not cover them.

For what the body-composition literature measures in the general population, and how rarely it measures function, see [what the body-composition studies measured](https://glpwatchdog.org/research/glp1-hair-loss-and-muscle-loss).

## Frequently asked questions

### Do GLP-1 drugs work for people with spinal cord injury?

The only study we could find is a controlled case series of five people. Over 26 weeks, the three who received weekly semaglutide lost on average 6 kg of body weight, 4.4 kg of fat mass and 674 cm³ of visceral fat, while the two untreated participants gained on all three measures.

### How strong is that evidence?

Weak, and the paper presents itself as preliminary. It is an open-label case series with three treated and two control participants. An average across three people can be driven by one. It justifies a proper trial rather than a conclusion.

### Why does so little research include people with SCI?

Obesity trials generally recruit ambulatory participants, and the standard interventions assume mobility. That leaves a population whose body composition tends to shift toward fat after injury with very little evidence to draw on.

### Are there specific risks after spinal cord injury?

This study does not address them. Gastrointestinal effects are common with these drugs, and bowel management after SCI follows specific routines, so that interaction is worth raising with the clinician managing your injury.

## References

1. Cirnigliaro CM, La Fountaine MF, Sauer SJ, et al. Preliminary observations on the administration of a glucagon-like peptide-1 receptor agonist on body weight and select carbohydrate endpoints in persons with spinal cord injury: A controlled case series. The Journal of Spinal Cord Medicine. 2024. PMID: 37158751. https://pubmed.ncbi.nlm.nih.gov/37158751/

---

Cite as: GLP Watchdog, Nora Bissett, "GLP-1 Drugs After Spinal Cord Injury: Three People Treated, Two Not", published 2026-08-21, updated 2026-10-27. https://glpwatchdog.org/research/glp1-after-spinal-cord-injury

Canonical HTML page: https://glpwatchdog.org/research/glp1-after-spinal-cord-injury

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.